Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

被引：0

作者：

Ait-Khaled, Mounir ^{[1
]}

Oyee, James ^{[2
]}

Ooi, Adrian Yit Reen ^{[3
]}

Wynne, Brian ^{[4
]}

Maldonado, Andres ^{[5
]}

Jones, Bryn ^{[1
]}

Wang, Tao ^{[6
]}

机构：

[1] ViiV Healthcare, 980 Great West Rd, Brentford TW8 9GS, Middx, England

[2] GSK, Brentford, England

[3] ViiV Healthcare, Singapore, Singapore

[4] ViiV Healthcare, Durham, NC USA

[5] ViiV Healthcare, Wavre, Belgium

[6] GSK, Shanghai, Peoples R China

来源：

OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 05期

关键词：

dolutegravir/lamivudine; elvitegravir; HIV-1; switch study; virologically suppressed; ANTIRETROVIRAL THERAPY; DISOPROXIL FUMARATE; HIV; DYSLIPIDEMIA; COBICISTAT; LAMIVUDINE; INFECTION; RISK;

D O I：

10.1093/ofid/ofae227

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)-based regimens. In this post hoc subgroup analysis, 144-week efficacy and tolerability of dolutegravir/lamivudine in participants who switched from elvitegravir/cobicistat/emtricitabine/TAF were consistent with the overall switch population.Clinical Trials Registration NCT03446573.

引用

下载

页数：4

共 8 条

[1] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
Osiyemi, Olayemi
De Wit, Stephane
Ajana, Faiza
Bisshop, Fiona
Portilla, Joaquin
Routy, Jean-Pierre
Wyen, Christoph
Ait-Khaled, Mounir
Leone, Peter
Pappa, Keith A.
Wang, Ruolan
Wright, Jonathan
George, Nisha
Wynne, Brian
Aboud, Michael
van Wyk, Jean
Smith, Kimberly Y.
CLINICAL INFECTIOUS DISEASES, 2022, 75 (06) : 975 - 986
[2] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
van Wyk, Jean
Ajana, Faiza
Bisshop, Fiona
De Wit, Stephane
Osiyemi, Olayemi
Sogorb, Joaquin Portilla
Routy, Jean-Pierre
Wyen, Christoph
Ait-Khaled, Mounir
Nascimento, Maria Claudia
Pappa, Keith A.
Wang, Ruolan
Wright, Jonathan
Tenorio, Allan R.
Wynne, Brian
Aboud, Michael
Gartland, Martin J.
Smith, Kimberly Y.
CLINICAL INFECTIOUS DISEASES, 2020, 71 (08) : 1920 - 1929
[3] Durable Efficacy of Switching From a 3-or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
De Wit, Stephane
Bonnet, Fabrice
Osiyemi, Olayemi
Bisshop, Fiona
Olalla, Julian
Routy, Jean-Pierre
Wyen, Christoph
Moodley, Riya
Pappa, Keith
Wang, Ruolan
Oyee, James
Saggu, Parminder
Letang, Emilio
Wynne, Brian
Jones, Bryn
Smith, Kimberly Y.
Ait-Khaled, Mounir
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (02) : 156 - 160
[4] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent
Post, Frank
Yazdanpanah, Yazdan
Schembri, Gabriel
Lazzarin, Adriano
Reynes, Jacques
Maggiolo, Franco
Yan, Mingjin
Abram, Michael
Tran-Muchowski, Cecilia
Cheng, Andrew
Rhee, Martin
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[5] Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3-or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Llibre, Josep M.
Brites, Carlos
Cheng, Chien-Yu
Osiyemi, Olayemi
Galera, Carlos
Hocqueloux, Laurent
Maggiolo, Franco
Degen, Olaf
Taylor, Stephen
Blair, Elizabeth
Man, Choy
Wynne, Brian
Oyee, James
Underwood, Mark
Curtis, Lloyd
Bontempo, Gilda
van Wyk, Jean
CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 720 - 729
[6] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial
Post, Frank A.
Yazdanpanah, Yazdan
Schembri, Gabriel
Lazzarin, Adriano
Reynes, Jacques
Maggiolo, Franco
Yan, Mingjin
Abram, Michael E.
Tran-Muchowski, Cecilia
Cheng, Andrew
Rhee, Martin S.
HIV CLINICAL TRIALS, 2017, 18 (03): : 135 - 140
[7] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
Molina, J-M
Gallant, J.
Orkin, C.
Negredo, E.
Bhatti, L.
Gathe, J.
Van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Vanveggel, S.
Opsomer, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
[8] Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
Orkin, C.
Molina, J-M
Gallant, J.
Negredo, E.
Gathe, J.
Eron, J.
van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Petrovic, R.
Opsomer, M.
HIV MEDICINE, 2018, 19 : S32 - S32

← 1 →